Scotland-based biotech Cytomos has launched its newly patented AuraCyt cell analysis technology brand.
According to the company, AuraCyt provides information on cell properties and can be incorporated in-line, allowing real-time monitoring of cell manufacturing events and predicting manufacturing success. It is designed to collect data that measures the intrinsic properties of individual cells in real-time, and to obtain a unique digital profile for subsequent analysis and characterisation.
Aimed at the biologics and cell and gene therapy sectors, the technology could enable the measurement of cells using a wide range of frequencies concurrently, to build a picture of the cells in high dimensional space.
Cytomos CEO, David Rigterink commented: “We have and are attracting the brightest minds to help drive forward our exciting scientific, technological, business, marketing and commercial objectives. Our technology can provide intrinsic cell analysis data at speed to enable critically important, better-informed decision-making much earlier and can streamline product development to greatly reduce the cost and time taken to complete R&D programmes, technology transfer events and scaled manufacture. The ability to fail faster and generate products that succeed will help ensure the delivery of more healthcare treatments to more patients and reduce healthcare costs.”